San­doz to in­vest $90M in Slove­nia site that will pro­duce biosim­i­lars

San­doz is in­vest­ing $90 mil­lion to build a biosim­i­lar de­vel­op­ment cen­ter in Ljubl­jana, Slove­nia, the sec­ond ma­jor in­vest­ment that the gener­ics mak­er has made in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA